Ng, Chee M <br/><br/>
Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis.  [electronic resource] 

 -  Pharmaceutical research  Jun 2006 
 - 1275-84 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article 
<br/><br/><label>ISSN: </label>0724-8741 
<br/><br/><label>Standard No.: </label>10.1007/s11095-006-0205-x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Body Surface Area<br/>Body Weight<br/>Breast Neoplasms--drug therapy<br/>Drug Administration Schedule<br/>Female<br/>Humans<br/>Infusions, Intravenous<br/>Middle Aged<br/>Models, Biological<br/>Ovarian Neoplasms--drug therapy<br/>Randomized Controlled Trials as Topic